Insights on Purity and Intactness of AAV Gene Therapy Vectors

The company’s gene therapy, AAVB-039, for the treatment of Stargardt disease progresses to a Phase I/II clinical trial.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

The industry is diversifying pipelines from traditional small-molecule drugs to embrace complex and exciting new modalities.

Learn Morewww.bio-rad.com/fluvaccine

Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.

The investment will be done over five years and will include new, state-of-the-art R&D facilities as well as new or expanded manufacturing sites in multiple US states.